Amid a reckoning for the gene therapy field, Vertex Pharmaceuticals has joined a growing list of companies paring back their ...

The FDA has freed Amgen’s mysterious early-stage obesity asset from a clinical hold, with the phase 1 study now enrolling ...

The United Kingdom aims to boost its life sciences profile as Aviva Capital Partners and Socius unveiled plans for a £1 ...

To REMS, or not to REMS. That, apparently, was the question for Cytokinetics, which has seen any potential approval for its ...

Scholar Rock is shaking up its executive team as it prepares to enter the commercial arena with the expected launch of spinal ...

HistoSonics is shopping for a potential buyer of its approach to destroying liver tumors with focused sound waves, according ...

Pliant Therapeutics will be cutting 45% of staffers as part of a “strategic restructuring of its workforce," the biotech ...

Tim Friede began willingly injecting himself with escalating doses of venom from 16 snake species. | Eighteen years ago, Tim Friede began willingly injecting himself with escalating doses of venom ...

Pfizer and Arvinas have axed two phase 3 trials from their estrogen receptor (ER) degrader R&D plan in the wake of mixed data ...

The National Institutes of Health (NIH) is making a major change to how grant recipients can use their funds. | The National ...

The U.S. government is putting down $500 million toward the development of a “universal” vaccine—a shot designed to protect ...

Following the launch of two new cancer tests—plus a third planned for before the end of 2025—Exact Sciences is nudging up its ...